No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HUGE240517P1000
- 0.85
- 0.000.00%
15min DelayClose Apr 25 09:31 ET
0.00High0.00Low
0.85Open0.85Pre Close0 Volume1 Open Interest1.00Strike Price0.00Turnover2087.71%IV-60.56%PremiumMay 17, 2024Expiry Date0.62Intrinsic Value100Multiplier4DDays to Expiry0.23Time Value100Contract SizeAmericanOptions Type-0.2379Delta0.3578Gamma0.45Leverage Ratio-0.0350Theta-0.0001Rho-0.11Eff Leverage0.0001Vega
Intraday
- 5D
- 1D
News
Express News | 'DEA Appears To Question Marijuana's Medical Value Despite Rescheduling Recommendation' - Marijuana Moment
FSD Pharma Advances MS Treatment Trials
Newsweek Reporter Kevin Sabet Says On X "I Can Now Say With Full Confidence That The Administrator Of DEA, Anne Milgram, Did Not Sign The Rescheduling Order, Breaking With Five Decades Of Precedent And Established Law And Regulations (Two Confidential...
Newsweek Reporter Kevin Sabet Says On X "I Can Now Say With Full Confidence That The Administrator Of DEA, Anne Milgram, Did Not Sign The Rescheduling Order, Breaking With Five Decades Of Precedent An
Express News | 'Declassifying Cannabis Still Leaves Pot Stocks In Limbo' - Wall Street Journal
FSD Pharma Trials Supplement for Alcohol Intoxication
DEA Moving To Reclassify Marijuana As Less Dangerous Drug
DEA Moving To Reclassify Marijuana As Less Dangerous Drug
Comments
$FSD Pharma(HUGE.US$
NEWS
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
NEWS
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
$FSD Pharma(HUGE.US$
NEWS
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
NEWS
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
$FSD Pharma(HUGE.US$ This sure was a disappointment! But its green! And thats sure better than red by any amount ![]()
2
$FSD Pharma(HUGE.US$ FSD Pharma Provides Update From Celly Nu's Partnership With Six+One For Beverage Product Unbuzzd
Benzinga· 8 mins ago
On April 25, 2024, Celly Nu announced a strategic partnership with Six+One, a purpose-driven branding, advertising, and production agency based in New York City.
FSD Pharma has also licensed unbuzzd, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving indiv...
Benzinga· 8 mins ago
On April 25, 2024, Celly Nu announced a strategic partnership with Six+One, a purpose-driven branding, advertising, and production agency based in New York City.
FSD Pharma has also licensed unbuzzd, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving indiv...
$FSD Pharma(HUGE.US$
NEWS
FSD Pharma Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, giving them a 180-day compliance period to meet the requirement or face potential delisting.
NEWS
FSD Pharma Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, giving them a 180-day compliance period to meet the requirement or face potential delisting.
Read more